ClinicalTrials.gg
CompletedNCT03953300CHINOOKUpdated Nov 13, 2026

Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

A Phase 4 interventional study of Benralizumab and Placebo in Asthma, sponsored by AstraZeneca. Completed at 35 sites in 5 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Updated Nov 13, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
27th of 39
75 · median 128
Started
2019
with 4 others
Phase 4
9 of 39
2 open now
Registered
26th of 39
by date
Lead sponsor
24 of 39
AstraZeneca

Among the 39 studies testing benralizumab in Asthma, this one is the 27th largest by enrollment, is one of 5 that started in 2019, is one of 9 in phase 4, and was the 26th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics.

Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication.

Patients who complete treatment will enter 4 weeks follow-up period.

03

Conditions studied

  • Asthma

Keywords

  • Asthma
  • Eosinophilic Asthma
  • Lung Diseases
  • Inhaled Corticosteroids
  • ICS
  • LABA
  • benralizumab
  • Fasenra
  • mechanism of action
  • remodeling
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 18 through 70 years.
  2. Physician-diagnosed asthma requiring continuous treatment with medium- or high-dose ICS plus LABA with or without additional controller medication for at least 12 months prior to Visit 1, and current treatment with high-dose ICS plus LABA for at least 3 months prior to Visit 1 with or without additional asthma maintenance medication.
  3. Morning pre-BD ≥50 to \<80% of predicted normal value (PNV) and ≥1 liter (L) or morning pre-BD FEV1 ≥ 50 to \< 90% of PNV, if historical pre-BD FEV1 value (within 12 months prior to screening visit) was \< 80% of PNV.
  4. A blood eosinophil count meeting any of 3 criteria: ≥300 cells/µL during screening or ≥ 220 to \< 300 cells/μL during screening and documented eosinophil count of ≥ 300 cells/μL in the past 12 months, or ≥150 to \<300 cells/µL during screening plus one of the following: presence of nasal polyps or pre-BD FVC \<65% predicted at Visit 2
  5. Negative pregnancy test.
  6. Asthma control questionnaire (ACQ-6) >1.5.
  7. Fewer than 12 exacerbations within the 6 months prior to Visit 3.

Exclusion criteria

Exclusion Criteria:

  1. Any disease or concomitant medication which could affect study results or safety of study participants, including:

    • current smokers
    • history of cancer
    • life-threatening asthma
    • pulmonary disease other than asthma
  2. Use of chronic medication or receipt of immunoglobulin (or blood products) within 30 days prior to the date is obtained.
  3. Previously received:

    • benralizumab
    • 30 days prior to the date of randomization.
    • bronchial thermoplasty in the last 24 months prior to Visit 1
    • any non-biologic within 30 days (or 5 half-lives) prior to the date informed consent is obtained, whichever is longer.
    • any marketed or investigational biologic for the treatment of asthma within 4 months (or 5 half-lives) prior to the date informed consent is obtained, whichever is longer.
  4. Currently pregnant, breastfeeding or lactating women.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Benralizumab

    Administrated subcutaneously (SC) every 4 weeks for the first 3 doses, then every 8 weeks

    Biological: Benralizumab

  • Placebo comparator
    Placebo

    Administrated subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks

    Biological: Placebo

Interventions

  • BiologicalBenralizumab

    Benralizumab: 30 mg/mL solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.

  • BiologicalPlacebo

    Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.

06

What researchers measure

Primary outcomes

  1. The change in eosinophil numbers expressed as number/mm2 in submucosa as measured by major basic protein (MBP) staining in endobronchial biopsies

    The change in eosinophil numbers expressed as number/mm2 in submucosa as measured by major basic protein (MBP) staining in endobronchial biopsies

    Time frame: From baseline to Week 48 (Visit 10)

  2. The change in airway wall area percentage as the overall median for airway generations 3 and 4 combined as measured by quantitative computed tomography (QCT) imaging

    The change in airway wall area percentage as the overall median for airway generations 3 and 4 combined as measured by quantitative computed tomography (QCT) imaging

    Time frame: From baseline to Week 48 (Visit 10)

Secondary outcomes

  1. The change in eosinophil numbers, expressed as number/mm2 in epithelium as measured by major basic protein (MBP) staining in endobronchial biopsies

    The change in eosinophil numbers, expressed as number/mm2 in epithelium as measured by major basic protein (MBP) staining in endobronchial biopsies

    Time frame: From baseline to Week 48 (Visit 10)

  2. The change in eosinophil numbers, expressed as number/mm2 in epithelium and submucosa as measured by major basic protein (MBP) staining in endobronchial biopsies

    The change in eosinophil numbers, expressed as number/mm2 in epithelium and submucosa as measured by major basic protein (MBP) staining in endobronchial biopsies

    Time frame: From baseline to Week 48 (Visit 10)

  3. Absolute change in air trapping of the lung with expiratory density less than -856 Hounsfield Units (HU), and as expiratory-to-inspiratory ratio of mean lung density on computed tomography (CT) scans

    Absolute change in air trapping of the lung with expiratory density less than -856 Hounsfield Units (HU), and as expiratory-to-inspiratory ratio of mean lung density on computed tomography (CT) scans

    Time frame: From baseline to Week 48 (Visit 10)

  4. Absolute change in air trapping/small airway obstruction derived from regional matching of the inspiratory/expiratory computed tomography (CT) scans

    Absolute change in air trapping/small airway obstruction derived from regional matching of the inspiratory/expiratory computed tomography (CT) scans

    Time frame: From baseline to Week 48 (Visit 10)

  5. Change in airway lumen volume and airway resistance as measured by quantitative computed tomography (QCT)

    Change in airway lumen volume and airway resistance as measured by quantitative computed tomography (QCT)

    Time frame: From baseline to Week 48 (Visit 10)

  6. Change in endobronchial biopsies on airway epithelial cell integrity

    Change in endobronchial biopsies on airway epithelial cell integrity

    Time frame: From baseline to Week 48 (Visit 10)

  7. Change in endobronchial biopsies on reticular basement membrane (RBM) thickening

    Change in endobronchial biopsies on reticular basement membrane (RBM) thickening

    Time frame: From baseline to Week 48 (Visit 10)

  8. Change in endobronchial biopsies on vascularization of the sub-mucosa

    Change in endobronchial biopsies on vascularization of the sub-mucosa

    Time frame: From baseline to Week 48 (Visit 10)

  9. Assessments of peripheral airway resistance measured by AO

    Assessments of peripheral airway resistance measured by AO

    Time frame: From baseline to Week 48 (Visit 10)

  10. Change in endobronchial biopsies on mucin 5AC, oligomeric mucus/gel-forming (MUC5AC)

    Change in endobronchial biopsies on mucin 5AC, oligomeric mucus/gel-forming (MUC5AC)

    Time frame: From baseline to Week 48 (Visit 10)

  11. Absolute change in R5-R20 (peripheral airway resistance defined as the difference in resistance between 5 Hz [R5, total respiratory system resistance] and 20 Hz [R20, central resistance]) as measured by airwave oscillometry (AO)

    Absolute change in R5-R20 (peripheral airway resistance defined as the difference in resistance between 5 Hz \[R5, total respiratory system resistance\] and 20 Hz \[R20, central resistance\]) as measured by airwave oscillometry (AO)

    Time frame: From baseline to Week 48 (Visit 10)

  12. Absolute change in area under the reactance curve (AX) as measured by airwave oscillometry (AO)

    Absolute change in area under the reactance curve (AX) as measured by airwave oscillometry (AO)

    Time frame: From baseline to Week 48 (Visit 10)

  13. Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) residual volume (RV)

    Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) residual volume (RV)

    Time frame: From baseline to Week 48 (Visit 10)

  14. Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) total lung capacity (TLC)

    Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) total lung capacity (TLC)

    Time frame: From baseline to Week 48 (Visit 10)

  15. Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) inspiratory capacity (IC)

    Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) inspiratory capacity (IC)

    Time frame: From baseline to Week 48 (Visit 10)

  16. Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) RV/TLC ratio

    Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) residual volume / total lung capacity (RV/TLC) ratio

    Time frame: From baseline to Week 48 (Visit 10)

  17. Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP)functional residual capacity (FRC)

    Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP)functional residual capacity (FRC)

    Time frame: From baseline to Week 48 (Visit 10)

  18. Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) vital capacity (VC)

    Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) vital capacity (VC)

    Time frame: From baseline to Week 48 (Visit 10)

  19. Absolute change in post-bronchodilator (BD) whole body plethysmogrpahy (WBP) residual volume (RV)

    Absolute change in post-bronchodilator (BD) whole body plethysmogrpahy (WBP) residual volume (RV)

    Time frame: From baseline to Week 48 (Visit 10)

  20. Absolute change in post-bronchodilator (BD) whole body plethysmogrpahy (WBP) total lung capacity (TLC)

    Absolute change in post-bronchodilator (BD) whole body plethysmogrpahy (WBP) total lung capacity (TLC)

    Time frame: From baseline to Week 48 (Visit 10)

  21. Absolute change in post-bronchodilator (BD) whole body plethysmogrpahy (WBP) inspiratory capacity (IC)

    Absolute change in post-bronchodilator (BD) whole body plethysmogrpahy (WBP) inspiratory capacity (IC)

    Time frame: From baseline to Week 48 (Visit 10)

  22. Absolute change in post-bronchodilator (BD) whole body plethysmogrpahy (WBP) RV/TLC ratio

    Absolute change in post-bronchodilator (BD) whole body plethysmogrpahy (WBP) residual volume / total lung capacity(RV/TLC) ratio

    Time frame: From baseline to Week 48 (Visit 10)

  23. Absolute change in post-bronchodilator (BD) whole body plethysmogrpahy (WBP)functional residual capacity (FRC)

    Absolute change in post-bronchodilator (BD) whole body plethysmogrpahy (WBP)functional residual capacity (FRC)

    Time frame: From baseline to Week 48 (Visit 10)

  24. Absolute change in post-bronchodilator (BD) whole body plethysmogrpahy (WBP) vital capacity (VC)

    Absolute change in post-bronchodilator (BD) whole body plethysmogrpahy (WBP) vital capacity (VC)

    Time frame: From baseline to Week 48 (Visit 10)

  25. Change from pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) to post-BD WBP residual volume (RV)

    Change from pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) to post-BD WBP residual volume (RV)

    Time frame: From baseline to Week 48 (Visit 10)

  26. Change from pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) to post-BD WBP total lung capacity (TLC)

    Change from pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) to post-BD WBP total lung capacity (TLC)

    Time frame: From baseline to Week 48 (Visit 10)

  27. Change from pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) to post-BD WBP inspiratory capacity (IC)

    Change from pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) to post-BD WBP inspiratory capacity (IC)

    Time frame: From baseline to Week 48 (Visit 10)

  28. Change from pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) to post-BD WBP RV/TLC ratio

    Change from pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) to post-BD WBP residual volume / total lung capacity (RV/TLC) ratio

    Time frame: From baseline to Week 48 (Visit 10)

  29. Change from pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) to post-BD WBP functional residual capacity (FRC)

    Change from pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) to post-BD WBP functional residual capacity (FRC)

    Time frame: From baseline to Week 48 (Visit 10)

  30. Change from pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) to post-BD WBP vital capacity (VC)

    Change from pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) to post-BD WBP vital capacity (VC)

    Time frame: From baseline to Week 48 (Visit 10)

  31. Change in post-bronchodilator (BD) forced expiratory volume in 1 second (FEV1) as measured by spirometry

    Change in post-bronchodilator (BD) forced expiratory volume in 1 second (FEV1) as measured by spirometry

    Time frame: From baseline to Week 48 (Visit 10)

  32. Change in post-bronchodilator (BD) forced vital capacity (FVC) as measured by spirometry

    Change in post-bronchodilator (BD) forced vital capacity (FVC) as measured by spirometry

    Time frame: From baseline to Week 48 (Visit 10)

  33. Change in post-bronchodilator (BD) FEV1/FVC as measured by spirometry

    Change in post-bronchodilator (BD) FEV1/FVC as measured by spirometry

    Time frame: From baseline to Week 48 (Visit 10)

  34. Change in basophil number (number/mm2) in endobronchial biopsies as measured by immunohistochemistry (IHC)

    Change in basophil number (number/mm2) in endobronchial biopsies as measured by immunohistochemistry (IHC)

    Time frame: From baseline to Week 48 (Visit 10)

  35. Absolute change from baseline to End of Treatment in mucus score assessed using computed tomography (CT) scans

    Absolute change from baseline to End of Treatment in mucus score assessed using computed tomography (CT) scans

    Time frame: From baseline to Week 48 (Visit 10)

Other outcomes

  1. The number of Adverse events (AEs)/serious adverse events (SAEs).

    To evaluate the safety and tolerability of benralizumab. The number of Adverse events (AEs)/serious adverse events (SAEs).

    Time frame: From baseline to Week 52 (Visit 11)

07

Study locations

35 sites
  • Research Site
    Birmingham, Alabama 35209, United States
  • Research Site
    Los Angeles, California 90033, United States
  • Research Site
    Jacksonville, Florida 32204, United States
  • Research Site
    Miami, Florida 33166, United States
  • Research Site
    Snellville, Georgia 30078, United States
  • Research Site
    Indianapolis, Indiana 46268, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Kansas City, Kansas 66160, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Bloomfield Hills, Michigan 48301, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    St Louis, Missouri 63156, United States
  • Research Site
    Maspeth, New York 11378, United States
  • Research Site
    New Bern, North Carolina 28562, United States
  • Research Site
    Winston-Salem, North Carolina 27104, United States
  • Research Site
    Pittsburgh, Pennsylvania 15213, United States
  • Research Site
    Galveston, Texas 77555, United States
  • Research Site
    Lewisville, Texas 75067, United States
  • Research Site
    Mansfield, Texas 76063, United States
  • Research Site
    Calgary, Alberta T2N 4Z6, Canada
  • Research Site
    Aalborg, 9000, Denmark
  • Research Site
    Aarhus N, 8200, Denmark
  • Research Site
    Copenhagen, 2400, Denmark
  • Research Site
    Hvidovre, 2650, Denmark
  • Research Site
    Næstved, 4700, Denmark
  • Research Site
    Odense C, 5000, Denmark
  • Research Site
    Vejle, 7100, Denmark
  • Research Site
    Gothenburg, 413 45, Sweden
  • Research Site
    Lund, 22185, Sweden
  • Research Site
    Cambridge, CB2 2QQ, United Kingdom
  • Research Site
    Headington, OX3 9DU, United Kingdom
  • Research Site
    Leicester, LE3 9QP, United Kingdom
  • Research Site
    Liverpool, L7 8XP, United Kingdom
  • Research Site
    London, W1G 8HU, United Kingdom
  • Research Site
    Wythenshawe, M23 9LT, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Oct 2026, 84 months.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 84 months is above that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2019
First posted
May 16, 2019
StartActual
Oct 8, 2019
Primary completionActual
Oct 20, 2026
CompletionActual
Oct 20, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 13, 2026
Primary completion
Oct 19, 2026→Oct 20, 2026 (actual)
Nov 13, 2026
Study completion
Oct 19, 2026→Oct 20, 2026 (actual)
Nov 13, 2026
Show all 2 updates
  1. Nov 13, 2026
    Active, not recruiting→Completed
    Primary completion Oct 19, 2026→Oct 20, 2026 (now actual)
    Study completion Oct 19, 2026→Oct 20, 2026 (now actual)
    + 1 other change: verification date
  2. Sep 25, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03953300
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 16, 2019
Start date
Oct 8, 2019
Primary completion
Oct 20, 2026
Completion
Oct 20, 2026
Last update
Nov 13, 2026

Study contacts

Mario Castro, MD
principal investigator · University of Kansas School of Medicine 3901 Rainbow Blvd. Kansas City, KS 66160, USA

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion